Clinical trials: completed, sponsored by Boryung Pharmaceutical Co., Ltd
Erosive Esophagitis
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
- Trial name
- NCT01499368
- Testing
- Lafutidine, Famotidine, Omeprazole
- Volunteers
- 495 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
FimasaRtan-basEd BP Targets After Drug SwitcHing
The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in…
- Trial name
- FRESH (NCT03649646)
- Where
- South Korea
- Volunteers
- 4,542 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
Evaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.
- Trial name
- NCT02385721
- Where
- South Korea
- Volunteers
- 601 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.
- Trial name
- NCT02704702
- Testing
- Fimasartan, Rosuvastatin, Fimasartan + Rosuvastatin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922480
- Testing
- Fimasartan, Losartan (Control)
- Volunteers
- 506 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922441
- Testing
- Fimasartan 60 mg group, Fimasartan 120 mg group, Reference (Valsartan 80 mg) group
- Volunteers
- 92 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd